Phase I study of CI-958 in children and adolescents with recurrent solid tumors

Cancer

Volumn 91, Issue 6, 2001, Pages 1166-1169

  Arndt, Carola A S ^a,c   Krailo, Mark D ^a   Liu Mares, Wen ^a   Anderson, Peter M ^b   Reaman, Gregory H ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

CI 958; Pediatric recurrent solid tumors; Pharmacology

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; HELICASE; INTERCALATING AGENT; LEDOXANTRONE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SOLID TUMOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOTENSION; INDAZOLES; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; NEUTROPENIA;

EID: 0035868439     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010315)91:6<1166::AID-CNCR1113>3.0.CO;2-Y     Document Type: Article

References (5)

1. Biochemical effects and interaction with DNA of the novel intercalator, CI-958
2. Biochemical pharmacology and DNA-drug interactions by CI-958, a new antitumor intercalator derived from a series of substituted 2H-[1]Benzothiopyrano[4,3,2-cd]indazoles
3. Antihelicase action of CI-958, a new drug for prostate cancer
4. Benzothio-pyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents: Synthesis and activity against murine leukemias
5. Characterization of drug resistance to the benzothiopyranoindazole, CI-958